Aprea AB
Records under this name other than patents Aprea AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Aprea AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,061,016 | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,759,361 | Azabicyclooctan-3-one derivatives and use thereof Formerly held Term ended Term ended Jun 2, 2025 · From the USPTO record | Term ended | Term ended Jun 2, 2025 | From the USPTO record |
| US 7,659,278 | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases Formerly held Term ended Term ended May 18, 2024 · From the USPTO record | Term ended | Term ended May 18, 2024 | From the USPTO record |
| US 7,348,330 | 1-azabicyclo [2,2,2] octan-3-one derivatives Formerly held Term ended Term ended Mar 31, 2022 · From the USPTO record | Term ended | Term ended Mar 31, 2022 | From the USPTO record |
| US 6,921,765 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors Formerly held Term ended Term ended Dec 30, 2021 · From the USPTO record | Term ended | Term ended Dec 30, 2021 | From the USPTO record |
| US 7,902,167 | Compounds and methods for down-regulating Wrap53 protein by RNA interference Lapsed on the fee record Ended Mar 8, 2015 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2015 | From the USPTO record |